Keywords: b-ms, licenses, anticancer, drugs, taiho, bristol-myers, squibb
B-MS Licenses Two Anticancer Drugs From Taiho
Article | 18 August 1997
- Bristol-Myers Squibb has licensed two anticancer compounds, S-1 andTAS-103, from the Japanese drugmaker Taiho Pharmaceutical. S-1 is said to be ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
